GlassScriptPhysician profile
Sabrina Davis
NPI 1376889063
$2,695.80
in general payments reported to CMS, 2019-2025
24 companies · $677 in 2025
The $677 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.49 · 2022: $114 · 2023: $831 · 2024: $1,020 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,528.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.72 | 2023-2025 | |
| Amgen INC. | $309.57 | 2023-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $193.82 | 2022-2025 | Ozempic, Wegovy |
| Alnylam Pharmaceuticals INC. | $175.55 | 2024 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $152.82 | 2023-2025 | Breztri, Tezspire, Airsupra |
| Paratek Pharmaceuticals, INC. | $138.03 | 2023-2024 | Nuzyra |
| Dexcom, INC. | $131.52 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Pfizer INC. | $124.77 | 2024 | |
| Eisai INC. | $109.22 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $99.36 | 2024 | Austedo Xr |
| Sumitomo Pharma America, INC. | $87.32 | 2023 | Gemtesa |
| Axsome Therapeutics, INC. | $83.92 | 2025 | Auvelity |
| Acadia Pharmaceuticals INC | $69.40 | 2023 | Nuplazid |
| Neurocrine Biosciences, INC. | $69.02 | 2023 | Ingrezza |
| Inspire Medical Systems, INC. | $66.48 | 2025 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $57.61 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $56.34 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $55.99 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $55.86 | 2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $53.58 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.62 | 2023-2024 | Xifaxan |
| Emd Serono, INC. | $31.09 | 2021 | |
| Akebia Therapeutics INC | $22.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.79 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabrina Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.